fbpx

QQQ
+ 2.31
364.32
+ 0.63%
BTC/USD
+ 1446.85
62322.42
+ 2.38%
DIA
+ 3.70
345.43
+ 1.06%
SPY
+ 3.26
439.24
+ 0.74%
TLT
-0.85
146.73
-0.58%
GLD
-2.66
170.66
-1.58%

Canopy Growth Analyst Sees Increasing Cannabis Market Share, Little Stock Upside

June 23, 2020 2:47 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Canopy Growth Analyst Sees Increasing Cannabis Market Share, Little Stock Upside

Canopy Growth Corp. (NYSE:CGC) shares traded higher on Tuesday after the company held a virtual meeting on Monday and reassured investors that the company is leading the cannabis group in three major long-term growth markets.

Canopy management said its long-term plan is to continue to focus on the Canadian market, the U.S. CBD market and the German market. The company’s total global addressable market is projected at $70 billion by 2023, and the U.S., Canada and Germany will account for 90% of that market.

From 2019 to 2023, Canopy is projecting the Canadian cannabis market will grow by 400%, the U.S. CBD market will grow by 600% and the German market will grow by 1,000%.

A Canopy Analyst's Take: BofA Securities analyst Bryan Spillane said Tuesday that Canopy also emphasized its advantages in R&D, consumer insights, supply chain infrastructure and capitalization.

“Opening more Canadian stores is not everything as CGC plans to adjust its product offerings in order to compete more effectively against the illegal market, not by just lowering prices but through offering superior consumer experiences,” the analyst said. 

Canopy also said it will update long-term financial guidance once COVID-19's impacts dissipate.

Canopy’s recreational Canadian sales were down 28% in the March quarter compared to 18% overall growth in sales for the market as a whole.

Canopy Valuation Concerns: Cantor Fitzgerald analyst Pablo Zuanic said Tuesday that Canopy is positioned well to regain lost market share in the Canadian market and help convert legacy illegal marijuana users to the legal market, particularly via the launch of edibles and beverages. 

Yet Zuanic sees little upside for the stock at today's valuation.

“If we assume a 25% share on the 2023 TAM opportunity and 20% EBITDA margins by then (although guidance points to 10-15%), and if we use a 0.5 wholesale deflator and 15-20x EV/EBITDA, this would mean an EV of only $8-11Bn, vs. C$8.2Bn at present,” he said Tuesday. 

Instead of Canopy, Zuanic prefers Canadian cannabis plays Aphria Inc (NASDAQ:APHA) and Aurora Cannabis Inc (NYSE:ACB).

Bank of America has a Buy rating and CA$30 ($21.70) price target for Canopy.

Cantor Fitzgerald has a Neutral rating with a price target lowered from CA$27 to CA$25.50. 

Benzinga’s Take: One potential catalyst for cannabis stocks with exposure to the U.S. market is the upcoming November election. Legalization measures are already on the ballot in four states, and advocates are collecting signatures to get additional measures on the 2020 ballot in six other states.

Do you agree with this take? Email feedback@benzinga.com with your thoughts.

Related Links:

Here's How Much Investing $100 In The 2018 Cronos Listing Would Be Worth Today

How Legalizing Marijuana Could Help Kick-Start The US Economy

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Related Articles

Is Aurora Cannabis' 'Business Transformation Plan' Yielding Results?

Is Aurora Cannabis' 'Business Transformation Plan' Yielding Results?

Aurora Cannabis (NASDAQ: ACB) (TSX: ACB) reported a 45% year-over-year plunge in consumer cannabis net revenue, while its total net revenue in the fourth quarte read more
Will Aurora Become A Global Medical Marijuana Leader? Analyst Opines Ahead Of Q4 Earnings

Will Aurora Become A Global Medical Marijuana Leader? Analyst Opines Ahead Of Q4 Earnings

Canadian cannabis giant Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB) reported a plunge in third-quarter sales months ago, in addition to a negative adjusted EBITDA of CA$24 million ($28.3 million). read more
Organigram On Pace To Beat Tilray And Hexo In QoQ Sales Growth As Canadian Rec. Sales Reach $275.6M

Organigram On Pace To Beat Tilray And Hexo In QoQ Sales Growth As Canadian Rec. Sales Reach $275.6M

As COVID-related restrictions begin to ease across the globe, some industries are feeling the benefits more than others. When it comes to Canadian recreational cannabis sales, new Hifyre scanner data reveals a 10% improvement sequentially, noted Cantor Fitzgerald’s Pablo Zuanic in his latest industry report. read more
Tilray, Aurora, Sundial, Hexo Q2 Market And Sales Trends, Cantor Fitzgerald Projects Stronger Q3

Tilray, Aurora, Sundial, Hexo Q2 Market And Sales Trends, Cantor Fitzgerald Projects Stronger Q3

As COVID-19 safety measures begin to slowly lift and more people are getting vaccinated, many industries are beginning to blossom. For the cannabis industry, in particular, this could mean an improved third quarter (compared to the second quarter) as restrictions began to ease in June, according to Cantor Fitzgerald’s Pablo Zuanic. read more